Site Map

Home
About Heart Failure
- Mechanism of Disease
- Disease Progression
HFrEF
HFpEF with LVEF ≤60%*
- Clinical & Biomarker Data
Safety & Dosing
- Safety
- Dosing
About ENTRESTO®
- Dual Mechanism of Action
Support & Resources
- Patient Resources

Important Safety Information

BOXED WARNING: FETAL TOXICITY

When pregnancy is detected, discontinue ENTRESTO as soon as possible
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

ENTRESTO is contraindicated in patients with hypersensitivity to any component...

Indication

ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.

LVEF is a variable measure, so use clinical judgment in deciding whom to treat.

Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

Contact Us
Non-US Residents
Sitemap
Medical Information
Interest-Based Ads

Use of website is governed by the Terms of Use and Privacy Policy.

3/25 FA-11377230

Site Map

Home

About Heart Failure

About Heart Failure

HFrEF

HFrEF

HFpEF with LVEF ≤60%*

HFpEF with LVEF ≤60%*

Safety & Dosing

Safety & Dosing

About ENTRESTO®

About ENTRESTO®

Support & Resources

Support & Resources